Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

AstraZeneca’s Lynparza recommended by the EMA for HRD-positive advanced ovarian cancer

AstraZeneca and MSD’s Lynparza (olaparib) has been recommended for marketing authorisation across the European Union for the first-line maintenance treatment with bevacizumab for patients with homologous recombination deficient (HRD)-positive Advanced Ovarian Cancer. This came after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) gave the recommendation based on […]

The post AstraZeneca's Lynparza recommended by the EMA for HRD-positive advanced ovarian cancer first appeared on World Pharma Today.



This post first appeared on Leading Pharmaceutical Industry Online Platform, please read the originial post: here

Share the post

AstraZeneca’s Lynparza recommended by the EMA for HRD-positive advanced ovarian cancer

×

Subscribe to Leading Pharmaceutical Industry Online Platform

Get updates delivered right to your inbox!

Thank you for your subscription

×